Companies › Electra Therapeutics
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ELA026 SIRP-directed monoclonal antibody | SIRPA | Phase 2 | Secondary Hemophagocytic Lymphohistiocytosis (sHLH); T Cell Malignancies | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05416307 | ELA026 | Phase 2 | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Hematology | Mar 2028 |
| NCT07465835 | ELA026 | Phase 1 | T Cell Malignancies | Oncology | Jun 2028 |
Press releases filed as 8-K in the last year:
Syntrix Biosystems Theravia Servier Affaires Médicales NanoEcho Syncromune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.